CHRISTOPHER CAUSEY - 04 Mar 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
Director
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol
UTHR
Transactions as of
04 Mar 2026
Net transactions value
-$9,803
Form type
4
Filing time
05 Mar 2026, 16:34:28 UTC
Previous filing
25 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CAUSEY CHRISTOPHER Director C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING /s/ John S. Hess, Jr. under Power of Attorney 05 Mar 2026 0001237334

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise +20 +0.48% $119.76* 4,210 04 Mar 2026 Direct F1
transaction UTHR Common Stock Sale $9,803 -20 -0.48% $490.17 4,190 04 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Option Options Exercise -20 -0.32% $0.000000* 6,300 04 Mar 2026 Common Stock 20 $119.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 30, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $490.12 to $490.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.